Global Health Investment Fund Purchases $8 Million of Convertible Notes Issued by Access Bio, Inc.

NEW YORK–(BUSINESS WIRE)– The Global Health Investment Fund (“GHIF”) is pleased to announce that
it has invested $8 million in Access Bio, Inc. (KOSDAQ:950130) (“ABI” or
“Access Bio”), a publicly listed company on South Korea’s KOSDAQ
exchange. The investment is structured as convertible notes which can be
exchanged for an equity interest in the company at GHIF’s discretion
after a fixed lock-up period. Investment proceeds will be used to
procure and install manufacturing equipment that will further support
the affordability of ABI’s rapid diagnostic test products.

Access Bio is an innovative point-of-care diagnostics company with a
growing portfolio of products that advance GHIF’s mission of making
high-quality, affordable medical technologies accessible in low- and
middle-income countries. Anchored by its position as a market-leading
provider of rapid diagnostic tests (“RDTs”) for malaria, Access Bio also
offers an expanding menu of robust, low-cost tests for public health
challenges such as HPV infection, glucose-6-phosphate dehydrogenase
deficiency, HIV infection, dengue fever and syphilis. In addition to the
company’s established product pipeline, Access Bio is also responding to
the emerging Zika virus threat through the development of diagnostic
products on both RDT and molecular testing platforms.

“Given Access Bio’s commitment to developing and delivering low-cost
diagnostic kits for such a wide range of conditions of interest to the
Global Health Investment Fund, we are thrilled to be providing financing
to support the company’s RDT manufacturing capabilities,” said Glenn
Rockman of GHIF. “We believe our support will enable further
enhancements to ABI’s RDT assembly process and we look forward to
continued collaboration with the company to ensure their entire
portfolio of diagnostic kits is widely available at affordable prices.”

Following the World Health Organization’s 2010 recommendation that all
suspected cases of malaria receive a diagnostic test prior to treatment,
malaria RDTs have become an essential public health commodity, with more
than 300 million tests delivered annually over the last three years. The
majority of these tests are purchased by international donors and public
health systems in malaria-endemic countries, where accurate diagnosis of
infection is enabling better patient care and more efficient use of
anti-malarial drugs. Diagnostic products such as those manufactured by
Access Bio are essential tools in advancing the control and elimination
agenda for malaria and other public health challenges.

Mr. Young H. Choi, chief executive officer of Access Bio, remarked that
“our financing agreement with Global Health Investment Fund further
solidifies our commitment to make high-quality diagnostic products
accessible to those most in need. We believe we can make a meaningful
impact in the lives of hundreds of millions of patients around the
world, while tapping into an enormous and rapidly growing customer base
that will benefit as affordable diagnostics play an increasing role in
managing the threat posed by infectious diseases.”

About Access Bio, Inc.:

Access Bio (KOSDAQ:950130) is dedicated to the prevention and early
diagnosis of infectious diseases through research, development, and
manufacturing of in vitro rapid diagnostic tests, biosensors and
molecular diagnostic products. The company’s in vitro diagnostic
test platform includes immunochemical, biochemical and molecular
products.

Headquartered in Somerset, New Jersey, Access Bio serves its global
customer base from manufacturing sites located in the US, Ethiopia and
South Korea. In fiscal year 2015, the company reported $31.4 million of
revenues, largely from sales of its industry-leading malaria RDT
products. The company is in the early stages of commercializing a number
of additional diagnostic kits that leverage its existing expertise and
manufacturing capacity.

For additional information about the company, please visit accessbio.net

About Global Health Investment Fund I, LLC:

GHIF is a private investment fund structured by JPMorgan Chase & Co. and
the Bill & Melinda Gates Foundation. The fund received anchor support
from Grand Challenges Canada (funded by the Government of Canada), the
German Ministry for Economic Cooperation and Development (acting through
KfW), the Swedish International Development Cooperation Agency and the
Children’s Investment Fund Foundation. The fund’s limited partners also
include AXA, GlaxoSmithKline, International Finance Corporation,
JPMorgan Chase & Co., Merck, Pfizer Foundation, Storebrand and
individual investors.

With an emphasis on late-stage projects, GHIF finances the development
of drugs, vaccines and diagnostics for diseases that disproportionately
burden low-income populations. Much like a traditional investment fund,
GHIF searches for opportunities that will deliver compelling financial
returns in developed markets and/or emerging markets. Of equal
importance, each investment must also advance the fund’s public health
mission, which is to ensure that the innovations it supports are
accessible to those who need them most in underserved markets. Key
global health challenges targeted by the fund include malaria,
tuberculosis, HIV/AIDS, cholera and preventable causes of maternal and
infant mortality, in addition to other neglected infectious diseases.
GHIF’s definition of success requires meaningful improvements in the
lives of those afflicted by these challenges, and the fund forecasts and
measures its progress against this objective alongside traditional
financial return benchmarks.

For additional information about GHIF, please visit ghif.com.

Image may be NSFW.
Clik here to view.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160330005328/en/